Searching. Please wait…
1582
37
171
29406
4423
2606
347
392
Abstract: Although new therapies have doubled the survival of multiple myeloma patients, this remains an incurable disease. It has been postulated that the so-called myeloma cancer stem cells would be responsible for tumor initiation and relapse but their unequivocal identification remains unclear. Here, we investigated in a panel of myeloma cell lines the presence of CD20+ cells harboring a stem-cell phenotype. Thus, only a small population of CD20dim+ cells (0.3%) in the RPMI-8226 cell line was found. CD20dim+ RPMI-8226 cells expressed the plasma cell markers CD38 and CD138 and were CD19?CD27?. Additionally, CD20dim+ RPMI-8226 cells did not exhibit stem-cell markers as shown by gene expression profiling and the aldehyde dehydrogenase assay. Furthermore, we demonstrated that CD20dim+ RPMI-8226 cells are not essential for CB17-SCID mice engraftment and show lower self-renewal potential than the CD20? RPMI-8226 cells. These results do not support CD20 expression for the identification of myeloma cancer stem cells.
Fuente: Haematologica, 2012, 97(7), 1110-1114
Publisher: Ferrata Storti Foundation
Year of publication: 2012
No. of pages: 5
Publication type: Article
DOI: 10.3324/haematol.2011.057372
ISSN: 0390-6078,1592-8721
Publication Url: https://doi.org/10.3324/haematol.2011.057372
SCOPUS
Citations
Google Scholar
Metrics
UCrea Repository Read publication
PAÍNO, TERESA
ENRIQUE MARIA OCIO SAN MIGUEL
PAIVA, BRUNO
SAN-SEGUNDO, LAURA
GARAYOA, MERCEDES
GUTIÉRREZ, NORMA C.
EUGENIA SARASQUETE M.
PANDIELLA, ATANASIO
ORFAO, ALBERTO
SAN MIGUEL, JESÚS F.
Back